Close Menu

NEW YORK (GenomeWeb) – Diagnostics firm OncoCyte announced today  that it has received approximately $2 million through the early exercise of 625,000 common stock purchase warrants by certain warrant holders.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.